Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magnus Lindskog

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
BJUI Compass|July 23, 2025
Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinomaAnna Brännbäck, Ivan Mustonen, Teemu D Laajala, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2020
An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancerGeorgios Tsakonas, Rolf Lewensohn, Johan Botling, et al.
International Journal of Molecular Sciences|January 8, 2023
Matched Analyses of Brain Metastases versus Primary Non-Small Cell Lung Cancer Reveal a Unique microRNA SignatureGeorgios Tsakonas, Andreas Koulouris, Dominika Kazmierczak, et al.
Scandinavian Journal of Urology|August 19, 2022
Surgical waiting times and all-cause mortality in patients with non-metastatic renal cell carcinomaAndreas Karlsson Rosenblad, Pernilla Sundqvist, Ulrika Harmenberg, et al.
Molecular Cancer Therapeutics|September 19, 2007
The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivoMalin Wickström, John Inge Johnsen, Frida Ponthan, et al.
Translational Lung Cancer Research|July 17, 2025
Predictors of survival and recurrence patterns following definitive chemoradiotherapy in stage III non-small cell lung cancer-a retrospective cohort studyErika Broström, Johan Isaksson, Panagiotis Xanthoulis, et al.
Acta Oncologica (Stockholm, Sweden)|October 3, 2025
Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumabAlaa Kheir, Berglind Johannsdottir, Alexandra Grönn-Weiss, et al.
Journal of Internal Medicine|February 14, 2026
Perioperative immune checkpoint inhibitor therapy across tumors: Insights and shared lessons from a rapidly evolving fieldKarl Björkström, Alexios Matikas, Fernanda Costa Svedman, et al.
F1000Research|January 17, 2019
Disulfiram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent glioblastoma (DIRECT): Study protocol for a randomized controlled trialAsgeir Store Jakola, Katja Werlenius, Munila Mudaisi, et al.
JAMA Network Open|March 31, 2023
Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical TrialKatja Werlenius, Sara Kinhult, Tora Skeidsvoll Solheim, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
BJUI Compass|July 23, 2025
Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinomaAnna Brännbäck, Ivan Mustonen, Teemu D Laajala, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2020
An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancerGeorgios Tsakonas, Rolf Lewensohn, Johan Botling, et al.
International Journal of Molecular Sciences|January 8, 2023
Matched Analyses of Brain Metastases versus Primary Non-Small Cell Lung Cancer Reveal a Unique microRNA SignatureGeorgios Tsakonas, Andreas Koulouris, Dominika Kazmierczak, et al.
Scandinavian Journal of Urology|August 19, 2022
Surgical waiting times and all-cause mortality in patients with non-metastatic renal cell carcinomaAndreas Karlsson Rosenblad, Pernilla Sundqvist, Ulrika Harmenberg, et al.
Molecular Cancer Therapeutics|September 19, 2007
The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivoMalin Wickström, John Inge Johnsen, Frida Ponthan, et al.
Translational Lung Cancer Research|July 17, 2025
Predictors of survival and recurrence patterns following definitive chemoradiotherapy in stage III non-small cell lung cancer-a retrospective cohort studyErika Broström, Johan Isaksson, Panagiotis Xanthoulis, et al.
Acta Oncologica (Stockholm, Sweden)|October 3, 2025
Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumabAlaa Kheir, Berglind Johannsdottir, Alexandra Grönn-Weiss, et al.
Journal of Internal Medicine|February 14, 2026
Perioperative immune checkpoint inhibitor therapy across tumors: Insights and shared lessons from a rapidly evolving fieldKarl Björkström, Alexios Matikas, Fernanda Costa Svedman, et al.
F1000Research|January 17, 2019
Disulfiram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent glioblastoma (DIRECT): Study protocol for a randomized controlled trialAsgeir Store Jakola, Katja Werlenius, Munila Mudaisi, et al.
JAMA Network Open|March 31, 2023
Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical TrialKatja Werlenius, Sara Kinhult, Tora Skeidsvoll Solheim, et al.
Pageof 5